Skip to main content
Monday, November 16, 2026Nov 16

FDA approves a second Alzheimer’s drug that can modestly slow disease

This image provided by Eli Lilly shows the company's new Alzheimer’s drug Kisunla.  The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday, July 2, 2024 for mild or early cases of dementia caused by Alzheimer’s. (Eli Lilly and Company via AP)
This image provided by Eli Lilly shows the company's new Alzheimer’s drug Kisunla. The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday, July 2, 2024 for mild or early cases of dementia caused by Alzheimer’s. (Eli Lilly and Company via AP)

WASHINGTON (AP) — U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.

The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar drug from Japanese drugmaker Eisai.

The delay seen with both drugs amounts to a matter of months — about seven months, in the case of Lilly’s drug. Patients and their families will have to weigh that benefit against the downsides, including regular IV infusions and potentially dangerous side effects like brain swelling.

Physicians who treat Alzheimer’s say the approval is an important step after decades of failed experimental treatments.

“I’m thrilled to have different options to help my patients,” said Dr. Suzanne Schindler, a neurologist at Washington University in St. Louis. “It’s been difficult as a dementia specialist — I diagnose my patients with Alzheimer’s and then every year I see them get worse and they progress until they die.”